“Bimekizumab 3-Year Maintenance of Response in Week 16 Responders With Moderate to Severe Plaque Psoriasis: Results from Five Phase 3 3b Trials”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s306, https://doi.org/10.25251/skin.8.supp.306.